Carillon Tower Advisers’s Novo Nordisk NVO Stock Holding History

Carillon Tower Advisers’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$6.87M	Sell	196,772 -16,236	-8%	-$561K	0.04%	372
2020 Q3	$7.39M	Sell	213,008 -17,440	-8%	-$581K	0.1%	291
2020 Q2	$7.54M	Sell	230,448 -116,682	-34%	-$3.72M	0.06%	327
2020 Q1	$10.4M	Sell	347,130 -40,230	-10%	-$1.2M	0.1%	265
2019 Q4	$11.2M	Sell	387,360 -15,050	-4%	-$417K	0.07%	316
2019 Q3	$10.4M	Sell	402,410 -48,324	-11%	-$1.22M	0.07%	327
2019 Q2	$11.5M	Sell	450,734 -16,888	-4%	-$417K	0.08%	324
2019 Q1	$12.2M	Sell	467,622 -25,406	-5%	-$624K	0.09%	306
2018 Q4	$11.4M	Sell	493,028 -93,990	-16%	-$2.09M	0.1%	289
2018 Q3	$13.8M	Sell	587,018 -63,756	-10%	-$1.56M	0.1%	291
2018 Q2	$15M	Buy	650,774 +33,756	+5%	+$802K	0.12%	260
2018 Q1	$15.2M	Buy	+617,018	New	+$16.2M	0.12%	240

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return

Carillon Tower Advisers's NVO Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Novo Nordisk (NVO) stake by 7.6% in Q4 2020, selling an estimated $561K and leaving 196,772 shares worth $6.87M. The position accounts for 0.04% of the portfolio, ranked #372.

Carillon Tower Advisers first reported a position in NVO in Q1 2018 and has held it in 12 quarters since. The position peaked at $15.2M in Q1 2018. 703 funds tracked by Wall St. Rank hold NVO as of Q4 2020.

Carillon Tower Advisers held 196,772 shares of Novo Nordisk worth $6.87M as of Q4 2020.
Carillon Tower Advisers sold 16,236 Novo Nordisk shares in Q4 2020, an estimated $561K.
Novo Nordisk made up 0.04% of Carillon Tower Advisers's portfolio in Q4 2020, its #372 holding.
Carillon Tower Advisers first reported a position in Novo Nordisk in Q1 2018 and has held it in 12 quarters since.
Carillon Tower Advisers's Novo Nordisk position peaked at $15.2M in Q1 2018.
703 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.